—

Genmab AS (GMAB) — the peer cohort

As of 2026-10-13 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Genmab AS ranks 7 of 7 in its cohort on the Closelooknet composite (51/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
GMAB Genmab AS 51 84 72 34 ok 9%
HALO Halozyme Therapeutics Inc 74 93 94 48 ok 6.2%
ARGX.BR Argen-X 63 53 75 29 info 22.3%
ONC BeiGene, Ltd. 63 75 62 30 info 9.4%
ARGX argenx NV ADR 62 47 74 29 info 25.2%
KRYS Krystal Biotech Inc 60 61 85 17 info 16%
REGN Regeneron Pharmaceuticals Inc 60 63 70 50 watch 11.2%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-13

Quick answers

Who are Genmab AS's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), Argen-X (ARGX.BR), BeiGene, Ltd. (ONC), argenx NV ADR (ARGX), Krystal Biotech Inc (KRYS), Regeneron Pharmaceuticals Inc (REGN).

How does GMAB score against its peers?

Genmab AS's composite reads 51/100, ranking 7 of 7 in its cohort as of 2026-10-13; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.